Home> Products> drive progress

{ "products": [ { "_id": "6958c5905a7ae6137dc2c613", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "iguratimod 25 mg", "description": "Introduction\n\nLiving with chronic joint pain, stiffness, and inflammation can quietly affect every part of daily life—from simple movements like walking and gripping objects to maintaining an active professional and social routine. Autoimmune conditions such as rheumatoid arthritis often progress slowly but steadily, making early and effective treatment essential for long-term joint health and quality of life.\n\nIBRUNITIME 25, containing Iguratimod 25 mg, is a disease-modifying antirheumatic drug (DMARD) developed to address the root cause of inflammatory joint diseases rather than merely masking symptoms. Unlike conventional painkillers that offer temporary relief, IBRUNITIME 25 works at the immune system level to reduce inflammation, slow joint damage, and improve overall physical function.\n\nThis medication is widely prescribed as part of long-term management strategies for inflammatory arthritis, particularly rheumatoid arthritis, helping patients regain mobility, reduce pain, and protect joint structure over time.\n\nComposition\n\nActive Ingredient: Iguratimod 25 mg\n\nBrand Name: IBRUNITIME 25\n\nDosage Form: Oral Tablet\n\nIguratimod is known for its immunomodulatory and anti-inflammatory properties, making it a valuable option in modern rheumatology care.\n\nHow IBRUNITIME 25 Works\n\nIguratimod works differently from standard anti-inflammatory medicines. Instead of only reducing pain signals, it directly influences immune system activity that leads to chronic inflammation.\n\nKey mechanisms include:\n\nSuppression of inflammatory cytokines such as interleukin-6 (IL-6)\n\nReduction of autoantibody production\n\nInhibition of processes that cause joint cartilage and bone damage\n\nBy targeting these underlying mechanisms, IBRUNITIME 25 helps slow disease progression and preserves joint integrity over time.\n\nUses of IBRUNITIME 25\n1. Rheumatoid Arthritis (RA)\n\nThe primary use of IBRUNITIME 25 is in the treatment of rheumatoid arthritis, a chronic autoimmune disorder characterized by joint pain, swelling, stiffness, and progressive joint destruction.\n\n2. Inflammatory Joint Disorders\n\nIBRUNITIME 25 may also be prescribed in other inflammatory joint conditions where immune-mediated inflammation plays a significant role.\n\n3. Combination Therapy\n\nIt is often used alongside other DMARDs such as methotrexate, depending on disease severity and patient response, to enhance treatment outcomes.\n\nKey Benefits of IBRUNITIME 25\n1. Reduces Joint Pain and Swelling\n\nRegular use helps significantly decrease pain, tenderness, and swelling in affected joints, making daily activities more manageable.\n\n2. Improves Joint Mobility\n\nBy controlling inflammation, IBRUNITIME 25 improves flexibility and range of motion, allowing patients to move more comfortably.\n\n3. Slows Disease Progression\n\nUnlike pain relievers, this medication helps slow the progression of rheumatoid arthritis and reduces long-term joint damage.\n\n4. Targets the Root Cause\n\nIBRUNITIME 25 works on immune pathways responsible for chronic inflammation, offering more comprehensive disease control.\n\n5. Enhances Quality of Life\n\nWith better pain control, improved mobility, and reduced stiffness, patients often experience improved physical independence and emotional well-being.\n\n6. Suitable for Long-Term Use\n\nWhen taken under medical supervision, it is designed for long-term disease management rather than short-term symptom relief.\n\nDosage and Administration\n\nThe usual recommended dose is Iguratimod 25 mg, taken once or twice daily, as prescribed by a healthcare professional.\n\nTablets should be swallowed whole with water.\n\nIt can be taken with or after food to minimize stomach discomfort.\n\nDosage duration depends on disease severity, response to treatment, and physician guidance.\n\nImportant: Do not adjust the dose or stop the medication without consulting your doctor, even if symptoms improve.\n\nPossible Side Effects of IBRUNITIME 25\n\nLike all medications, IBRUNITIME 25 may cause side effects, although not everyone experiences them. Most side effects are mild to moderate and manageable with proper medical supervision.\n\nCommon Side Effects\n\nMild stomach discomfort\n\nNausea\n\nDiarrhea\n\nDizziness\n\nHeadache\n\nLess Common Side Effects\n\nElevated liver enzymes\n\nFatigue\n\nSkin rash\n\nLoss of appetite\n\nRare but Serious Side Effects\n\nLiver function abnormalities\n\nSevere allergic reactions\n\nSignificant gastrointestinal issues\n\nPatients are usually advised to undergo periodic blood tests to monitor liver function and overall health during treatment.\n\nPrecautions and Warnings\n\nLiver Health: Patients with existing liver disorders should use IBRUNITIME 25 cautiously and only under medical supervision.\n\nPregnancy and Breastfeeding: Not recommended unless clearly advised by a doctor.\n\nAlcohol Consumption: Excessive alcohol intake should be avoided due to potential liver strain.\n\nInfections: Inform your doctor if you have active or recurrent infections, as immune modulation may affect infection resistance.\n\nDrug Interactions: Always disclose current medications, supplements, or herbal products to your healthcare provider.\n\nWho Should Avoid IBRUNITIME 25?\n\nIndividuals with severe liver disease\n\nPatients with known hypersensitivity to Iguratimod\n\nPregnant or breastfeeding women (unless specifically prescribed)\n\nStorage Instructions\n\nStore at room temperature\n\nKeep away from moisture and direct sunlight\n\nKeep out of reach of children\n\nDo not use after the expiry date\n\nConclusion\n\nIBRUNITIME 25 (Iguratimod 25 mg) represents a modern, targeted approach to managing rheumatoid arthritis and chronic inflammatory joint disorders. By addressing the immune-driven causes of inflammation rather than simply relieving pain, it offers long-term benefits such as reduced joint damage, improved mobility, and enhanced quality of life.\n\nWhen used responsibly under medical supervision, IBRUNITIME 25 can become an essential part of a comprehensive arthritis management plan—helping patients move with confidence, reduce daily discomfort, and regain control over their health journey.\n\nIf you or your patients are seeking a dependable disease-modifying therapy that balances effectiveness with tolerability, IBRUNITIME 25 stands as a reliable and clinically valuable option in rheumatology care.", "price": 308.0, "discountamount": 93.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2260, "imageuri": "https://productimages.withfloats.com/actual/6958c5977b11f839cdd4d298.png", "tileimageuri": "https://productimages.withfloats.com/tile/6958c5977b11f839cdd4d298.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-01-03T07:30:24.617Z", "updatedon": "2026-01-08T05:30:16.841Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/iguratimod-25-mg/2260", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IBRUNITIME 25", "category": "ORTHOLOGYRANG", "tags": [ "iguratimod 25 mg.", "iguratimod 25 mg uses", "tab iguratimod 25 mg", "iguratimod 25 mg tablet uses", "iguratimod 25 mg tablet.", "tablet iguratimod 25 mg.", "tab iguratimod 25 mg uses.", "iguratimod 25 mg price.", "tab iguratimod 25 mg uses in hindi.", "iguratimod 25 mg tab" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694cf85408591c1173b54c2f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Pregabalin Epalrestat and Methylcobalamin Tablets", "description": "EPSTATE ED represents an advanced pharmaceutical formulation that combines three powerful therapeutic agents: Pregabalin, Epalrestat, and Methylcobalamin. This innovative triple-combination medication is specifically designed to address the complex pathophysiology of diabetic neuropathy and neuropathic pain conditions. By integrating multiple mechanisms of action, EPSTATE ED offers a comprehensive approach to managing nerve-related complications that significantly impact the quality of life for millions of individuals worldwide.\nThe formulation addresses not only the symptomatic relief of neuropathic pain but also targets the underlying metabolic derangements that contribute to nerve damage progression. This multi-pronged therapeutic strategy makes EPSTATE ED particularly valuable for patients who require more than symptomatic management alone.\nUnderstanding the Active Components\nPregabalin: The Neuropathic Pain Modulator\nPregabalin serves as the cornerstone analgesic component in EPSTATE ED. This anticonvulsant medication works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. Through this mechanism, Pregabalin reduces the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. This reduction in neurotransmitter release effectively dampens the abnormal neural signaling that characterizes neuropathic pain conditions.\nThe molecule demonstrates excellent bioavailability and rapid absorption, allowing patients to experience relief within a relatively short timeframe. Its efficacy in managing various neuropathic pain syndromes has been extensively documented in clinical trials, establishing it as a first-line agent for diabetic peripheral neuropathy, postherpetic neuralgia, and other chronic neuropathic pain conditions.\nEpalrestat: The Aldose Reductase Inhibitor\nEpalrestat represents a unique addition to the formulation, functioning as a selective aldose reductase inhibitor. In diabetic conditions, excess glucose is converted to sorbitol through the polyol pathway, with aldose reductase serving as the rate-limiting enzyme. The accumulation of sorbitol within nerve cells leads to osmotic stress, depletion of myoinositol, and subsequent nerve dysfunction.\nBy inhibiting aldose reductase, Epalrestat prevents this harmful sorbitol accumulation, thereby addressing one of the fundamental metabolic abnormalities responsible for diabetic neuropathy. This disease-modifying approach distinguishes EPSTATE ED from purely symptomatic treatments. Epalrestat has been particularly well-studied in Asian populations and has demonstrated the ability to improve nerve conduction velocities and reduce subjective neuropathic symptoms over time.\nMethylcobalamin: The Neurotropic Vitamin\nMethylcobalamin, the bioactive form of Vitamin B12, completes the therapeutic triad in EPSTATE ED. Unlike cyanocobalamin, which requires conversion in the body, methylcobalamin is immediately available for utilization in crucial biochemical processes. It plays an indispensable role in myelin synthesis, the protective sheath surrounding nerve fibers that enables proper signal transmission.\nThis coenzyme participates in methionine synthesis and is essential for maintaining the structural and functional integrity of neurons. Methylcobalamin also facilitates nerve regeneration and has demonstrated neuroprotective properties in various experimental models. For patients with diabetic neuropathy, who often exhibit Vitamin B12 deficiency (sometimes exacerbated by metformin therapy), supplementation with methylcobalamin addresses both nutritional deficits and supports nerve health at a fundamental level.\nClinical Applications and Uses\nEPSTATE ED is primarily indicated for the comprehensive management of diabetic peripheral neuropathy, a condition affecting approximately 50% of individuals with long-standing diabetes. The symptoms of this condition range from tingling sensations and burning pain to numbness and loss of protective sensation, which can lead to serious complications including foot ulcers and amputations.\nBeyond diabetic neuropathy, EPSTATE ED may be prescribed for various neuropathic pain syndromes where the combination of pain relief, metabolic correction, and nerve support proves beneficial. Patients experiencing chronic nerve pain resulting from metabolic disturbances, nutritional deficiencies, or structural nerve damage may find this combination particularly effective.\nThe medication is typically recommended for adults who have not achieved adequate symptom control with single-agent therapy or who would benefit from the synergistic effects of the three components. Healthcare providers may prescribe EPSTATE ED when a patient requires both immediate symptom relief and long-term disease modification.\nKey Benefits and Therapeutic Advantages\nComprehensive Multi-Mechanism Action\nThe primary advantage of EPSTATE ED lies in its multi-faceted approach to neuropathic conditions. Rather than addressing only pain symptoms, the formulation simultaneously tackles pain perception, underlying metabolic abnormalities, and nutritional support for nerve health. This comprehensive strategy may lead to superior outcomes compared to monotherapy approaches.\nEnhanced Pain Relief\nClinical evidence supporting Pregabalin's efficacy in neuropathic pain is substantial. Patients often report significant reductions in pain intensity, improved sleep quality due to decreased nocturnal pain, and enhanced ability to perform daily activities. The pain-relieving effects typically manifest within the first week of therapy and continue to improve with ongoing treatment.\nDisease Modification Potential\nUnlike purely symptomatic treatments, the inclusion of Epalrestat provides genuine disease-modifying potential. By targeting the polyol pathway, EPSTATE ED may slow the progression of nerve damage in diabetic patients. Long-term use may preserve nerve function and prevent the worsening of neuropathic symptoms, offering hope beyond mere symptom management.\nImproved Nerve Conduction and Function\nThe combination of metabolic correction through Epalrestat and neurotropic support via Methylcobalamin creates an environment conducive to nerve regeneration and functional improvement. Studies have demonstrated improvements in nerve conduction velocity parameters with similar combination therapies, suggesting potential restoration of nerve function rather than simple symptom masking.\nConvenience of Combination Therapy\nFor patients who would otherwise require multiple separate medications, EPSTATE ED offers the convenience of a single tablet containing all three therapeutic agents. This simplification of medication regimens improves compliance, reduces pill burden, and may enhance overall treatment outcomes.\nQuality of Life Enhancement\nThe cumulative effect of pain reduction, improved nerve function, and better metabolic control translates into meaningful quality of life improvements. Patients report better mobility, reduced interference of pain with daily activities, improved mood, and enhanced social functioning.\nPotential Side Effects and Safety Considerations\nCommon Side Effects\nAs with any pharmaceutical agent, EPSTATE ED may produce certain adverse effects. The most commonly reported side effects are primarily attributable to the Pregabalin component and include dizziness, somnolence, peripheral edema, dry mouth, blurred vision, weight gain, and difficulty with concentration or attention. These effects are generally mild to moderate and often diminish with continued therapy as the body adapts to the medication.\nGastrointestinal symptoms such as constipation or nausea may occur, though they are typically manageable with dietary modifications or symptomatic treatment. Some patients experience increased appetite leading to weight gain, which requires monitoring, particularly in diabetic individuals where weight management is crucial.\nSerious but Rare Adverse Events\nThough uncommon, certain serious adverse effects warrant immediate medical attention. These include allergic reactions manifesting as rash, itching, swelling, severe dizziness, or breathing difficulties. Pregabalin has been associated with rare cases of angioedema, which requires prompt discontinuation and medical intervention.\nMental health changes, including mood alterations, anxiety, depression, agitation, or suicidal thoughts, have been reported with Pregabalin use, particularly in individuals with pre-existing psychiatric conditions. Patients and caregivers should remain vigilant for behavioral changes and report them immediately to healthcare providers.\nDrug Interactions and Precautions\nEPSTATE ED may interact with other central nervous system depressants, including alcohol, opioids, benzodiazepines, and antihistamines, potentially intensifying sedation and cognitive impairment. Patients should inform their healthcare provider of all medications, supplements, and substances they consume.\nIndividuals with kidney impairment require dose adjustments since Pregabalin is primarily eliminated through renal excretion. Regular monitoring of renal function may be necessary during long-term therapy.\nSpecial Population Considerations\nPregnant or breastfeeding women should use EPSTATE ED only when clearly necessary and under strict medical supervision, as the safety profile in these populations has not been fully established. Elderly patients may be more susceptible to side effects, particularly dizziness and confusion, necessitating careful dose titration and monitoring.\nPatients should be advised against abrupt discontinuation of EPSTATE ED, as sudden cessation of Pregabalin may precipitate withdrawal symptoms including insomnia, nausea, headache, anxiety, and sweating. Gradual dose reduction under medical supervision is recommended when discontinuing therapy.\nDosage and Administration Guidelines\nThe appropriate dosage of EPSTATE ED is highly individualized and should be determined by a qualified healthcare professional based on the patient's specific condition, response to therapy, and tolerance. Typically, treatment begins with a lower dose that is gradually increased to achieve optimal therapeutic benefit while minimizing adverse effects.\nPatients should take EPSTATE ED exactly as prescribed, with or without food, at consistent times each day to maintain stable blood levels. Missing doses should be addressed by taking the forgotten dose as soon as remembered, unless it's nearly time for the next scheduled dose. Double dosing to compensate for missed doses is not recommended.\nRegular follow-up appointments allow healthcare providers to assess treatment efficacy, monitor for adverse effects, and make necessary dose adjustments. Patients should maintain open communication with their medical team regarding symptom improvement, side effects, and any concerns that arise during therapy.\nPatient Counseling and Lifestyle Recommendations\nMaximizing the benefits of EPSTATE ED extends beyond simply taking the medication. Patients should be counseled on complementary lifestyle measures that support neuropathy management. Maintaining optimal glycemic control remains paramount for diabetic patients, as blood sugar management directly impacts neuropathy progression regardless of medication.\nRegular physical activity, within individual capabilities, promotes circulation, supports nerve health, and may enhance the therapeutic effects of EPSTATE ED. Daily foot examinations become critical for diabetic patients to identify potential injuries early, preventing serious complications.\nNutritional optimization, including adequate intake of B vitamins, antioxidants, and essential nutrients, supports the neurotropic effects of Methylcobalamin. Avoiding alcohol and tobacco, both of which can exacerbate neuropathy, is strongly recommended.\nPatients should be cautioned about activities requiring alertness, such as driving or operating machinery, especially during the initial treatment phase when dizziness and somnolence may be more pronounced. These effects typically improve with continued therapy, but individual responses vary.\nConclusion\nEPSTATE ED represents a thoughtfully designed pharmaceutical formulation that addresses the multifaceted nature of diabetic neuropathy and neuropathic pain through its unique combination of Pregabalin, Epalrestat, and Methylcobalamin. This triple-action approach offers patients more than symptomatic relief—it provides genuine disease modification potential, nutritional support, and comprehensive nerve health optimization.\nThe synergistic effects of these three components create a therapeutic profile that is greater than the sum of its parts. While Pregabalin efficiently manages pain symptoms and improves quality of life in the short term, Epalrestat works to address underlying metabolic derangements that drive disease progression, and Methylcobalamin provides essential neurotropic support for nerve regeneration and function.\nFor patients struggling with the debilitating effects of neuropathic pain and diabetic neuropathy, EPSTATE ED offers renewed hope for better symptom control and potentially slowed disease progression. The convenience of combination therapy in a single tablet improves adherence and simplifies complex treatment regimens.\nHowever, EPSTATE ED is not without considerations. Potential side effects, though generally manageable, require awareness and monitoring. The medication is most effective when integrated into a comprehensive management plan that includes optimal glycemic control, lifestyle modifications, and regular medical supervision.\nUltimately, EPSTATE ED should be viewed as a valuable tool in the therapeutic arsenal against neuropathic conditions, best utilized under the guidance of knowledgeable healthcare professionals who can individualize treatment to each patient's unique needs and circumstances. With proper use, monitoring, and patient education, EPSTATE ED can significantly improve outcomes and quality of life for those affected by these challenging neurological conditions.", "price": 275.0, "discountamount": 82.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2253, "imageuri": "https://productimages.withfloats.com/actual/694cf859d25fa0b0657b1ac8.png", "tileimageuri": "https://productimages.withfloats.com/tile/694cf859d25fa0b0657b1ac8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-25T08:39:48.947Z", "updatedon": "2026-01-10T06:06:36.677Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/pregabalin-epalrestat-and-methylcobalamin-tablets/2253", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "EPSTATE ED", "category": "NEUROLOGYRANGE", "tags": [ "regabalin, Epalrestat, and Methylcobalamin.neuropathic pain conditions.", "Pregabalin, Epalrestat, and Methylcobalamin.", "neuropathic pain.", "diabetic neuropathy.", "sorbitol within nerve cells leads to osmotic stress.", "Epalrestat and neurotropic support via Methylcobalamin creates an environment .", "mood alterations, anxiety, depression, agitation.", "supports the neurotropic effects of Methylcobalamin." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694919f0de5d3e57a93413a8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "elagolix 150mg tablet", "description": "Eligolux 150 delivers 150mg of elagolix per tablet, formulated as an oral, once-daily option in convenient packs for ongoing therapy. As a non-peptide GnRH receptor antagonist, it selectively suppresses pituitary gonadotropins, reducing ovarian estrogen production without the flare effect of agonists. Ideal for patients with milder symptoms or those prioritizing bone health, this dose minimizes hypoestrogenic risks while targeting endometriotic pain.\n\nTake Eligolux 150 whole with water, with or without food, preferably at the same time daily. Storage requires a cool, dry environment below 30°C, away from children and moisture. Steris Healthcare ensures GMP-compliant manufacturing, making it accessible across India for endometriosis care.\n\nPrimary Uses and Indications\nEligolux 150 primarily treats moderate endometriosis-associated pain, including dysmenorrhea, chronic pelvic discomfort, and dyspareunia. Endometriosis impacts 10% of reproductive-age women, causing ectopic endometrial growth that triggers inflammation and scarring; elagolix 150mg curbs estrogen-driven progression.\n​\nPrescribed when NSAIDs or combined pills prove inadequate, it excels in non-severe cases, allowing prolonged use. Emerging evidence supports its role in heavy menstrual bleeding from fibroids, though primary approval focuses on pain relief. Start therapy within the first week of menses for optimal synchronization.\n​\nMechanism of Action\nElagolix in Eligolux 150 competitively binds GnRH receptors, dose-dependently inhibiting LH/FSH release. This lowers estradiol by 40-60%—less aggressive than 200mg—halting endometrial tissue proliferation outside the uterus. Peak levels hit in 1 hour, with a 4-6 hour half-life supporting steady-state suppression on QD dosing.\n​\nUnlike agonists, no initial hormone surge occurs, preventing worsened pain. Partial estrogen reduction preserves some bone-protective effects, differentiating it from deeper suppression therapies.\n\nKey Benefits\nEligolux 150 shines in clinical responsiveness: phase 3 trials showed 32% dysmenorrhea resolution versus 20% placebo at 6 months, with 50% pain score drops. Quality-of-life gains include better work attendance, sleep, and relationships, per EQ-5D assessments.\n​\nExtended 24-month approval suits long-term control, with amenorrhea in 40-50% of users reducing bleeding volume by 70%. Oral ease beats injectables, enhancing adherence at 85% in studies. Lower BMD impact (0.5-1% loss/year) allows safer continuation versus higher doses.\n\nBenefit\tTrial Data\tPatient Impact\nPain Reduction\t32-50% dysmenorrhea-free \n​\tDaily activity restoration\nBleeding Control\t70% volume drop \n​\tAnemia prevention\nLong-Term Use:\tUp to 24 months \n​\tSustained relief\nQoL Improvement\tEQ-5D gains \n​\tEmotional well-being\nPotential Side Effects\nVasomotor symptoms dominate: hot flashes (20-30%), headaches (17%), and night sweats (10-15%) emerge early but fade. Nausea (8%), insomnia (7%), and mild depression (5%) affect minorities, with a 70% event rate mostly grade 1.\n​\nBMD decline averages -0.9% at the spine after 12 months, monitored via DEXA. Discontinuation hovers at 5-8%.\n\nSide Effect\tIncidence\tMitigation\nHot Flashes\t20-30% \n​\tVentilation, timing\nHeadache\t17% \n​\tAnalgesics\nBMD Loss\t0.9% \n​\tSupplements, scans\nMood Shifts\t5% \n​\tMonitoring\nSerious Risks and Management\nSuicidality (0.1-0.5%) demands baseline psych screening; halt if worsening. Liver enzymes rise in 1%, requiring LFTs at 3/6 months. Rare anaphylaxis or thromboembolism prompts immediate cessation. Avoid in osteoporosis or smokers >35.\n​\n\nDosage Guidelines\n150 mg once daily for up to 24 months in normal/mild liver function; limit to 6 months in moderate impairment (Child-Pugh B). No titration needed; miss a dose? Resume the next day, no doubling. Pair with 1 g calcium/800 IU vitamin D daily.\n​\n\nPrecautions and Contraindications\nPregnancy category X: mandates non-hormonal birth control during and 1 week post-therapy. Screen hepatic/renal function; avoid severe cases. CYP3A interactions (e.g., rifampin reduces efficacy) need dose review. Breastfeeding is contraindicated.\n​\nClinical Evidence and Efficacy\nElaris trials (n=1,689) confirmed superiority: co-primary endpoints met with 75% responder rates for pain. 12-month extensions showed persistent efficacy and low rebound. Versus 200mg, 150mg balances tolerability for moderate pain.\n​\nConclusion\nEligolux 150 empowers women with moderate endometriosis pain through precise, extended hormonal modulation and proven outcomes. Regular physician oversight maximizes safety and efficacy.\n", "price": 700.0, "discountamount": 210.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2252, "imageuri": "https://productimages.withfloats.com/actual/694a2af01e4092f757d90bb5.png", "tileimageuri": "https://productimages.withfloats.com/tile/694a2af01e4092f757d90bb5.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-22T10:14:08.773Z", "updatedon": "2026-01-09T05:31:32.372Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/elagolix-150mg-tablet/2252", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ELIGOLUX 150", "category": "Gynaecology", "tags": [ "elagolix 150mg tablet", "prioritizing bone health.", "endometriotic pain.", "endometrial tissue proliferation outside the uterus.", "Eligolux 150 empowers women with moderate endometriosis pain through precise.", "hormonal modulation and proven outcomes.", "gonadotropins.", "endometriotic pain." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6943af86161ad9de85f42b10", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "imatinib 400mg", "description": "IMATIFLOW 400, containing Imatinib IP 400mg, represents a breakthrough in targeted cancer therapy, offering patients a precise weapon against specific malignancies. This oral medication belongs to the class of tyrosine kinase inhibitors, revolutionizing treatment for conditions once deemed challenging to manage. By blocking abnormal proteins that fuel cancer cell growth, IMATIFLOW 400 helps restore normal cellular function and improves quality of life for many users.​\n\nProduct Overview\nIMATIFLOW 400 is a branded formulation of Imatinib mesylate 400mg, produced to high pharmaceutical standards for consistent efficacy and bioavailability. Each tablet delivers the active ingredient in a film-coated form, designed for once-daily administration with food to enhance absorption and minimize gastrointestinal upset. Developed for adult patients, it targets cancers driven by dysregulated tyrosine kinases like BCR-ABL, c-KIT, and PDGFR, making it a cornerstone in modern oncology protocols.​\n\nThe medication's mechanism hinges on competitive inhibition at the ATP-binding site of these kinases, halting downstream signaling pathways that promote uncontrolled proliferation, survival, and metastasis of malignant cells. Unlike traditional chemotherapy, which broadly attacks dividing cells, IMATIFLOW 400 spares most healthy tissues, leading to a more favorable safety profile. Clinical data from pivotal trials underscore its role as first-line therapy, with high response rates observed within months of initiation.​\n\nPrimary Uses\nIMATIFLOW 400 excels in treating chronic myeloid leukemia (CML), particularly in the chronic phase where it induces deep molecular responses in over 80% of patients. It suppresses the Philadelphia chromosome-positive cells hallmark of CML by inhibiting the BCR-ABL fusion protein, dramatically extending progression-free survival. For newly diagnosed patients, standard dosing starts at 400mg daily, often achieving complete cytogenetic remission.​\n\nIn gastrointestinal stromal tumors (GIST), IMATIFLOW 400 targets KIT or PDGFRA mutations, shrinking unresectable tumors and delaying progression in advanced cases. The recommended dose remains 400mg once daily, with potential escalation to 600-800mg for resistant strains, as per oncology guidelines. It also finds application in dermatofibrosarcoma protuberans (DFSP), aggressive systemic mastocytosis, and certain myelodysplastic syndromes, broadening its utility in precision medicine.​\n\nHealthcare providers monitor response via PCR for BCR-ABL transcripts in CML or imaging for GIST, adjusting therapy based on milestones like major molecular response. Patients with Ph+ acute lymphoblastic leukemia (ALL) may receive it adjunctively, enhancing outcomes when combined with chemotherapy. Overall, IMATIFLOW 400 transforms these diseases from fatal to chronically manageable.​\n\nKey Benefits\nOne standout benefit of IMATIFLOW 400 is its oral convenience, eliminating the need for frequent hospital visits associated with infusions. Response rates exceed 90% in early CML, with many patients achieving treatment-free remission after sustained deep responses, a paradigm shift from interferon-era therapies.​\n\nTumor control in GIST prevents life-threatening complications like bowel obstruction, improving survival from months to years. Its specificity reduces severe toxicities, allowing patients to maintain daily activities, work, and social engagements with minimal disruption. Long-term studies report 10-year survival rates above 80% in CML, underscoring durable efficacy.​\n\nAdditional advantages include cost-effectiveness over biologics and compatibility with supportive care like hydroxyurea for cytoreduction. Fluid retention, while common, responds well to diuretics, preserving cardiac function. For Indian patients, accessible pricing via brands like IMATIFLOW 400 supports equitable care in resource-limited settings.​\n\nPotential Side Effects\nWhile generally well-tolerated, IMATIFLOW 400 can cause edema (swelling in legs or face) in up to 70% of users, managed by dose reduction or supportive measures. Gastrointestinal issues like nausea, vomiting, and diarrhea affect 40-50%, often resolving with antiemetics and dietary adjustments.​\n\nMusculoskeletal pain, cramps, and fatigue occur frequently, alongside rash and abdominal discomfort. Hematologic effects include neutropenia or thrombocytopenia, necessitating regular blood counts. Rare but serious risks involve liver enzyme elevation, heart failure, or hemorrhage; prompt reporting of symptoms like shortness of breath or yellowing skin is crucial.​\n\nAvoid grapefruit juice, as it elevates drug levels, and inform doctors of concurrent medications like CYP3A4 inhibitors. Pregnancy category D status advises contraception, with monitoring for growth retardation in exposed fetuses. Dizziness may impair driving, so caution is essential during initial weeks.​\n\nDosage and Administration Guidelines\nSwallow IMATIFLOW 400 whole with a meal and full glass of water to optimize pharmacokinetics and reduce esophageal irritation. The standard adult dose for CML chronic phase is 400mg daily; for accelerated phase or blast crisis, 600mg. GIST dosing mirrors 400mg, titrated based on tolerance and response.​\n\nRenal or hepatic impairment requires dose adjustments—reduce to 300-400mg in moderate cases. Do not crush or chew tablets. Missed doses should be taken promptly unless near the next, avoiding doubles. Long-term use demands quarterly monitoring of CBC, liver function, and ECG.​\n\nPrecautions and Interactions\nPatients with a cardiac history need baseline echocardiograms, as QT prolongation or effusion risks exist. Drug interactions abound: St. John's wort induces metabolism, reducing efficacy; ketoconazole boosts levels. Vaccines, especially live ones, are contraindicated during therapy.​\n\nRegular dermatologic checks mitigate skin cancer risk from prolonged use. Hydration combats fluid retention, and low-salt diets aid management. Steris Healthcare emphasizes patient education via counseling on adherence for optimal outcomes.​\n\nConclusion\nIMATIFLOW 400 (Imatinib IP 400mg) stands as a testament to targeted therapy's power, offering robust control over CML, GIST, and related cancers with a balance of efficacy and manageability. Its benefits in prolonging life and enhancing daily functioning far outweigh transient side effects for most when monitored diligently. Consult oncologists for personalized plans, ensuring this innovative treatment maximizes hope and health in the fight against cancer.", "price": 1827.0, "discountamount": 540.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2249, "imageuri": "https://productimages.withfloats.com/actual/6943b026ca1b0dcfc6c37820.png", "tileimageuri": "https://productimages.withfloats.com/tile/6943b026ca1b0dcfc6c37820.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-18T07:38:46.766Z", "updatedon": "2026-01-08T07:15:13.88Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/imatinib-400mg/2249", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IMATIFLOW 400", "category": "NEPHROLOGYRANGE", "tags": [ "Imatinib IP 400mg", "offering robust control over CML.", "related cancers with a balance of efficacy and manageability.", "innovative treatment maximizes hope and health in the fight against cancer.", "cancer therapy.", "fuel cancer cell growth.", "chemotherapy.", "imatinib 400mg.", "imatinib 400mg tablet.", "tab. imatinib 400mg.", "imatinib 400mg price.", "imatinib 400mg tab", "imatinib 400mg side effects.", "imatinib 400 mg tablet", "imatinib 400 mg medicine", "imatinib tablets 400 mg uses", "imatinib 400 mg dosage", "imatinib 400 mg price in india", "imatinib 400 mg brand name" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6932959513286b8c66d8786f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Myoinositol 600mg + Metformin SR 500", "description": "OVOCYST M is a specialized sustained-release tablet combining Myoinositol 600mg and Metformin SR 500mg, primarily designed to address polycystic ovary syndrome (PCOS) and related metabolic issues in women. This formulation from Steris Healthcare Pvt Ltd targets insulin resistance, hormonal imbalances, and ovulatory dysfunction, making it a go-to option for restoring reproductive wellness. By improving insulin sensitivity and ovarian function, OVOCYST M supports regular cycles and fertility outcomes effectively.​\n\nProduct Composition and Mechanism\nOVOCYST M features Myoinositol 600mg, a natural insulin signaling mediator that enhances cellular health and oocyte quality in PCOS patients. Paired with Metformin SR 500mg, a sustained-release biguanide that lowers hepatic glucose production and boosts peripheral insulin uptake, this duo tackles root causes like hyperinsulinemia. The SR technology ensures gradual release, minimizing digestive upset while providing prolonged metabolic support throughout the day.​\n\nThis synergistic action restores ovulatory cycles by balancing hormones such as FSH and LH, reducing androgen excess common in PCOS. Women experiencing anovulation or irregular menses find OVOCYST M particularly beneficial as it promotes follicular development without aggressive interventions.​\n\nKey Uses of OVOCYST M\nOVOCYST M excels in managing PCOS symptoms, including irregular menstrual cycles and infertility linked to insulin resistance. Healthcare providers often prescribe it for hyperandrogenism, where elevated male hormones cause hirsutism or acne, alongside metabolic syndrome features like obesity.​\n\nSupports fertility treatments by improving egg quality and implantation rates in assisted reproduction.​\nAids weight management in PCOS by curbing insulin-driven fat accumulation.​\nRegulates blood sugar in prediabetic women with PCOS, preventing progression to type 2 diabetes.​\nTypically taken once or twice daily with meals, the dosage aligns with physician guidance for optimal results over 4-12 weeks.​\n\nMajor Benefits for PCOS and Beyond\nOne standout advantage of OVOCYST M is its ability to normalize ovulation, with studies showing improved cycle regularity in up to 70-80% of users. By enhancing insulin sensitivity, it reduces hyperinsulinemia, alleviating symptoms like fatigue and cravings that hinder daily life.​\n\nPromotes modest weight loss (2-5kg over months) through better metabolic control, boosting self-esteem and mobility.​\n\nEnhances fertility by maturing oocytes and lowering miscarriage risks in PCOS pregnancies.​\n\nLowers androgen levels, clearing skin issues and reducing unwanted hair growth for aesthetic and emotional relief.​\n\nLong-term use under supervision sustains these gains, fostering holistic health improvements like better energy and mood stability.​\n\nPotential Side Effects and Precautions\nWhile generally well-tolerated, OVOCYST M may cause mild gastrointestinal effects such as nausea, flatulence, or a metallic taste from Metformin. These often subside with time or food intake, thanks to the SR formulation's gentler profile.​\n\nRare but serious risks include lactic acidosis in those with kidney/liver issues, warranting avoidance in such cases. Precautions involve monitoring blood sugar, avoiding during acute illnesses, and consulting doctors if pregnant or breastfeeding.​\n\nCommon: Bloating or diarrhea, manageable by starting low dose.​\n\nConsult promptly for persistent vomiting or weakness.​\n\nConclusion\nOVOCYST M stands as a reliable, science-backed ally for women battling PCOS, insulin resistance, and fertility hurdles through its potent Myoinositol 600mg and Metformin SR 500mg blend. Delivering tangible benefits like restored cycles, weight control, and enhanced conception chances, it empowers proactive reproductive health management. Always pair with lifestyle tweaks like balanced diet and exercise for peak efficacy, and rely on professional oversight for safe, sustained results—transforming challenges into opportunities for vitality.", "price": 257.0, "discountamount": 77.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2233, "imageuri": "https://productimages.withfloats.com/actual/693295fa395d93bf6f980d94.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/693295fa395d93bf6f980d94.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-05T08:19:33.812Z", "updatedon": "2025-12-05T08:19:33.812Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/myoinositol-600mg-metformin-sr-500/2233", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "OVOCYST M", "category": "Gynaecology", "tags": [ "Myoinositol 600mg and Metformin SR 500mg", "polycystic ovary syndrome (PCOS)", "OVOCYST M supports regular cycles and fertility" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "692ed8ebf342eae689c9cf04", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "CIPVISION GOLD", "description": "CIPVISION GOLD stands out as a premium nutritional supplement crafted to safeguard and enhance vision in today's digital age. This unique blend combines Lutein, Zeaxanthin, Astaxanthin, Acetylcysteine, and Melatonin, delivering comprehensive support for retinal health, oxidative stress reduction, and circadian rhythm balance essential for optimal eye function. Ideal for prolonged screen users, aging adults, and those exposed to blue light, CIPVISION GOLD promotes clearer vision, reduces fatigue, and protects against age-related macular degeneration (AMD).​\n\nEach softgel capsule provides synergistic doses of these potent antioxidants and neuroprotective agents, formulated for daily use to maintain sharp eyesight and overall ocular wellness. By targeting multiple pathways of eye damage, it addresses modern lifestyle challenges like dry eyes, blurred vision, and night vision issues effectively.\n\nProduct Composition and Uses of CIPVISION GOLD\nCIPVISION GOLD features a scientifically balanced composition centered on eye-protective carotenoids and supportive compounds. Lutein and Zeaxanthin (typically 10-20mg combined) form the macular pigment, filtering harmful blue light and UV rays to prevent retinal damage. Astaxanthin (4-12mg), a super-antioxidant from microalgae, combats inflammation and improves blood flow to the eyes, enhancing visual acuity.\n\nAcetylcysteine (as N-acetylcysteine, NAC, around 200-600mg) acts as a mucolytic and glutathione precursor, clearing oxidative debris and supporting corneal health while reducing cataract risk. Melatonin (1-3 mg) regulates sleep-wake cycles, which are crucial for eye repair during rest, and offers neuroprotective effects against glaucoma progression. Primary uses of CIPVISION GOLD include preventing AMD, alleviating computer vision syndrome (CVS), managing dry eye syndrome, supporting post-cataract recovery, and improving night vision in diabetics or the elderly.\n\nTaken once daily with meals, it integrates seamlessly into routines for proactive eye care, with benefits accumulating over 3-6 months of consistent use.\n\nKey Benefits of CIPVISION GOLD\nCIPVISION GOLD unlocks multifaceted advantages for eye health through its powerhouse ingredients:\n\nBlue Light Protection: Lutein and Zeaxanthin build a natural shield in the macula, reducing photostress and improving contrast sensitivity for screen-heavy lifestyles.\n\nPowerful Antioxidant Defense: Astaxanthin neutralizes free radicals 6000 times more effectively than vitamin C, preserving photoreceptor cells and slowing AMD onset.\n\nTear Film Stability and Detox: Acetylcysteine boosts glutathione levels, thinning mucus for better lubrication and detoxifying lens proteins to maintain clarity.\n\nSleep and Recovery Support: Melatonin enhances deep sleep phases, promoting retinal regeneration and lowering intraocular pressure for glaucoma prevention.\n\nEnhanced Visual Performance: Users report sharper focus, less eye strain, and better adaptation to low light, ideal for drivers and gamers.\n\nClinical insights suggest these components synergize to lower oxidative markers by up to 40%, outperforming single-nutrient formulas for long-term vision preservation.\n\nPotential Side Effects and Safety Profile\nCIPVISION GOLD maintains an excellent tolerability profile, with most users experiencing no adverse effects due to its natural, bioavailable ingredients. Mild, transient issues may arise initially:\n\nCommon side effects include slight digestive upset (nausea or bloating from high-dose carotenoids), vivid dreams from melatonin, or yellowing of skin/stool from excess lutein—harmless and dose-dependent. Rare allergic responses like rash or itching warrant discontinuation.\n\nCategory\tPossible Side Effects\tManagement Tips\nGastrointestinal\tMild nausea, diarrhea\tTake with food ​\nNeurological\tDrowsiness (melatonin)\tEvening dosing\nSkin/Ocular\tTemporary yellow tint\tNormal carotenoid effect\nAllergic\tRash, swelling\tStop use and consult a doctor.\nSerious risks remain minimal absent contraindications like pregnancy (avoid high melatonin), autoimmune conditions (NAC caution), or bilirubin issues. Interactions with blood thinners or sedatives require medical oversight.\n\nDosage Recommendations and Best Practices\nAdults take one CIPVISION GOLD softgel daily, preferably with a fat-containing meal to boost carotenoid absorption. For intensive needs (e.g., heavy screen time), physicians may advise two capsules, not exceeding 3 months without review. Store in a cool, dry place; shake before use if settling occurs.\n\nPair with lifestyle tweaks: 20-20-20 rule for screens, UV sunglasses, and omega-3 rich diet for amplified results. Regular eye exams track progress, ensuring sustained efficacy.\n\nConclusion: Elevate Your Vision with CIPVISION GOLD\nCIPVISION GOLD redefines eye supplementation by harnessing Lutein, Zeaxanthin, Astaxanthin, Acetylcysteine, and Melatonin for unparalleled protection against modern threats to eyesight. From shielding retinas to fostering repair, it empowers clearer, fatigue-free vision for vibrant living. Integrate it today under professional guidance to future-proof your eyes effectively.", "price": 340.0, "discountamount": 102.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2226, "imageuri": "https://productimages.withfloats.com/actual/6952232785771224761cd7d7.png", "tileimageuri": "https://productimages.withfloats.com/tile/6952232785771224761cd7d7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-02T12:17:47.626Z", "updatedon": "2026-01-03T07:01:25.874Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/cipvision-gold/2226", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Steris Healthcare Pvt Ltd", "category": "GENERAL RANGE", "tags": [ "crafted to safeguard and enhance vision in today's digital age.", "eye nourishment for aging eyesight.", "tear film stability supplement.", "advanced eye health supplement tablets.", "optimal eye function.", "less eye strain.", "Interactions with blood thinners or sedatives require medical oversight." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "666abe06cee93a1bbc383645", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "nicoumalone 2mg", "description": "NICOMALOM 2 \nNICOMALOM 2 features Nicoumalone, also known as Acenocoumarol, as its active ingredient in a 2mg tablet formulation. This medication belongs to the coumarin class of anticoagulants, which work by interfering with the liver's production of vitamin K-dependent clotting factors like II, VII, IX, and X. Unlike newer direct oral anticoagulants, NICOMALOM 2 offers a well-established profile with adjustable dosing based on individual INR monitoring, ideal for personalized treatment plans. Each tablet is crafted for easy oral administration, typically once daily, ensuring consistent blood thinning without the need for injections.\n​\n\nThe formulation ensures rapid absorption, with peak effects within hours, allowing for effective clot prevention in high-risk scenarios. Steris Healthcare emphasizes quality manufacturing standards, making NICOMALOM 2 suitable for adults managing chronic conditions or post-surgical recovery. Its compact packaging of 10 tablets per strip supports convenient storage and portability for ongoing therapy.\n​\n\nKey Uses\nNICOMALOM 2 excels in preventing and treating thromboembolic disorders where blood clots pose immediate dangers. Primary applications include deep vein thrombosis (DVT), where clots form in deep leg veins, and pulmonary embolism (PE), a potentially fatal blockage in lung arteries. Physicians also prescribe it to reduce stroke risk in patients with atrial fibrillation, a common irregular heartbeat that promotes clot formation in the heart.\n​\n\nBeyond these, NICOMALOM 2 prevents clots after surgeries like hip or knee replacements, or in those with mechanical heart valves. It supports prophylaxis in recurrent clotting episodes, ensuring smoother blood flow and oxygen delivery to vital organs. For patients in Jaipur and Rajasthan facing high incidences of cardiovascular issues due to lifestyle factors, this medication provides targeted protection tailored to regional healthcare needs.\n​\n\nMechanism of Action\nNICOMALOM 2 disrupts the clotting cascade by blocking vitamin K epoxide reductase, an enzyme essential for regenerating vitamin K. This inhibition halts the activation of prothrombin and other coagulation factors, thinning the blood and preventing new clot formation while allowing existing ones to dissolve naturally. The result is improved vascular patency, reducing symptoms like leg swelling in DVT or breathlessness in PE.\n​\n\nTherapeutic levels are maintained through regular INR testing, typically targeting 2.0-3.0 for most indications, which differentiates it from fixed-dose alternatives. This precise control minimizes over-anticoagulation risks, making it suitable for long-term use in diverse patient profiles, including the elderly under careful supervision.\n​\n\nKey Benefits\nPatients using NICOMALOM 2 experience significant reductions in clot-related hospitalizations, with studies showing up to 80% lower stroke incidence in atrial fibrillation cases. Its oral convenience enhances adherence compared to injectables, promoting better quality of life for those with mobility limitations post-surgery. Cost-effectiveness positions it as an accessible option in India's pharmaceutical market, especially for Steris Healthcare clients optimizing SEO-driven healthcare content.\n​\n\nAdditional advantages include reversibility with vitamin K administration in emergencies and compatibility with dietary adjustments for stable INR. For pharmaceutical marketers, NICOMALOM 2's established safety data supports strong branding in neurology and cardiology segments, driving patient trust and repeat prescriptions.\n​\n\nBenefit\tDescription\tClinical Impact \n​\nStroke Prevention\tLowers risk in atrial fibrillation by 60-70%\tFewer neurological emergencies\nPost-Surgical Protection\tReduces thromboembolism after orthopedic procedures\tShorter recovery times\nDVT/PE Management\tHalts clot progression effectively\tImproved mobility and oxygenation\nLong-Term Safety\tAdjustable dosing via INR monitoring\tSustained therapy without frequent switches\nAffordability\tCompetitive pricing in Indian market\tHigh accessibility for diverse demographics\nPotential Side Effects\nWhile effective, NICOMALOM 2 carries bleeding risks as its primary concern, including easy bruising, gum bleeding, or prolonged cuts. Common gastrointestinal issues like nausea, vomiting, or diarrhea affect some users, often manageable by taking with food. Less frequent effects encompass hair loss, skin rashes, or itching, which typically resolve with dose adjustments.\n​\n\nRare but serious reactions involve heavy menstrual bleeding, nosebleeds, or internal hemorrhage signaled by black stools or blood in urine—prompt medical attention is crucial. Elderly patients or those with liver/kidney impairment face heightened sensitivity, necessitating baseline assessments. Interactions with antibiotics, NSAIDs, or vitamin K-rich foods like spinach can amplify effects, underscoring the need for holistic patient education.\n​\nSide Effect Category\tExamples\tManagement Tips \n​\nCommon (Mild)\tBruising, nausea, diarrhea\tTake with meals; monitor diet\nSerious (Bleeding)\tNosebleeds, heavy periods, wounds\tSeek immediate care; INR checks\nRare\tHair loss, rash, appetite loss\tDose tweak; symptomatic relief\nDrug/Food Interactions\tWarfarin-like potentiators, greens\tInform doctor of all intake\nDosage and Safety Precautions\nStandard initial dosing starts at 2-4 mg daily, titrated per INR response, often 1-10mg maintenance. Children and the elderly require caution with lower starts. Avoid abrupt stops to prevent rebound clotting; inform surgeons/dentists pre-procedure. Pregnant or breastfeeding women should consult alternatives due to fetal risks.\n​\nRegular prothrombin time tests ensure efficacy, with lifestyle advice like avoiding contact sports minimizing injury. Store at room temperature, away from moisture.\n​\nConclusion\nNICOMALOM 2 delivers robust anticoagulation for clot prevention, balancing potent benefits against manageable risks through vigilant monitoring. For patients and healthcare providers in pharmaceutical hubs like Jaipur, it remains a cornerstone therapy, enhancing outcomes in DVT, PE, and beyond. Always prioritize professional guidance for optimal results.", "price": 227.0, "discountamount": 68.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "DVT", "food", "heart", "water", "Doses", "EMAIL", "tablet", "patients", "Benefits", "NICOMALOM", "synthesis", "same time", "Nicoumalone", "2 mg dosage", "INR) levels", "information", "Introduction", "Key Features", "sterisonline", "initial dose", "sterispharma", "long-term use", "CALL/WHATSAPP", "Administration", "Initial Dosage", "target INR range", "prothrombin time", "most indications", "maintenance dose", "affordable option", "careful monitoring", "Maintenance Dosage", "chronic conditions", "pulmonary embolism", "healthcare provider", "regular blood tests", "atrial fibrillation", "Standardized Dosing", "precise adjustments", "deep vein thrombosis", "blood clot formation", "Long-Term Management", "thromboembolic events", "Stroke Risk Reduction", "typical starting dose", "regular INR monitoring", "consistent blood levels", "optimal anticoagulation", "thromboembolic disorders", "Thromboembolism Prevention", "International Normalized Ratio", "potent anticoagulant medication", "vitamin K-dependent clotting factors" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1860, "imageuri": "https://productimages.withfloats.com/actual/666abe098b71a2cb2d7d3c68.png", "tileimageuri": "https://productimages.withfloats.com/tile/666abe098b71a2cb2d7d3c68.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-13T09:38:14.673Z", "updatedon": "2026-01-05T08:10:43.679Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/nicoumalone-2mg/1860", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "NICOMALOM 2 ", "category": "NEUROLOGYRANGE", "tags": [ "nicoumalone 2mg uses", "nicoumalone tablet", "nicoumalone tablets side effects", "nicoumalone tablet dosage", "nicoumalone drug interactions" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6662e74687f0960e14a2d95a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Gefitinib 250mg", "description": "\n\nGEFISTERIS 250 is a premium pharmaceutical formulation containing Gefitinib 250mg, a breakthrough targeted therapy medication manufactured by Steris Healthcare. This innovative oral medication represents a significant advancement in the treatment of non-small cell lung cancer (NSCLC), offering patients a precise, scientifically-designed approach to combating one of the world's most challenging malignancies. GEFISTERIS 250 is specifically engineered to target the underlying molecular mechanisms that drive certain types of lung cancer, providing hope and extended survival for patients who carry specific genetic mutations.\nAs a tyrosine kinase inhibitor, GEFISTERIS 250 works at the cellular level to interrupt the signals that tell cancer cells to grow and divide. This targeted approach differs fundamentally from traditional chemotherapy, which affects both healthy and cancerous cells. By focusing specifically on cancer cells with epidermal growth factor receptor (EGFR) mutations, GEFISTERIS 250 offers a more refined treatment strategy with potentially fewer systemic side effects and improved quality of life during treatment.\nUnderstanding Gefitinib 250mg: The Science Behind GEFISTERIS 250\nGefitinib 250mg, the active pharmaceutical ingredient in GEFISTERIS 250, belongs to a revolutionary class of medications known as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). The development of this medication marked a paradigm shift in oncology, moving from one-size-fits-all chemotherapy approaches to personalized, mutation-specific treatments.\nThe EGFR protein is found on the surface of cells and plays a crucial role in cell growth and division. In normal cells, EGFR activation is carefully regulated. However, in certain lung cancers, mutations in the EGFR gene cause the receptor to remain constantly active, sending continuous signals for the cell to grow, divide, and survive—leading to uncontrolled cancer growth. GEFISTERIS 250 works by blocking the tyrosine kinase activity of the mutated EGFR protein, effectively turning off the growth signal and causing cancer cells to stop proliferating and eventually die.\nThis precision targeting is what makes GEFISTERIS 250 particularly effective for patients whose tumors harbor activating EGFR mutations, particularly the common exon 19 deletions or exon 21 L858R substitution mutations. Before initiating treatment with GEFISTERIS 250, patients undergo molecular testing to confirm the presence of these mutations, ensuring that the therapy is appropriately matched to their specific cancer biology.\nPrimary Uses and Indications of GEFISTERIS 250\nGEFISTERIS 250 is primarily indicated for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors have specific EGFR mutations. The medication is approved for both first-line treatment in newly diagnosed patients and for those whose disease has progressed after platinum-based chemotherapy.\nFirst-Line Treatment: When EGFR mutations are detected in treatment-naïve patients, GEFISTERIS 250 offers an excellent first-line option, often providing superior progression-free survival compared to traditional chemotherapy regimens. Patients starting with targeted therapy typically experience better tolerability and quality of life during initial treatment phases.\nSecond-Line and Beyond: For patients whose cancer has progressed after chemotherapy, GEFISTERIS 250 provides an effective alternative treatment option, particularly when EGFR mutation testing was not performed initially or when the mutation status was unknown at the time of first treatment.\nThe medication is taken orally as a once-daily tablet, offering significant convenience compared to intravenous chemotherapy that requires hospital visits and lengthy infusion times. This oral administration allows patients to maintain greater independence and normalcy in their daily lives while receiving effective cancer treatment.\nKey Benefits of GEFISTERIS 250\n1. Targeted Cancer Fighting Action\nThe primary benefit of GEFISTERIS 250 lies in its precision targeting mechanism. Unlike conventional chemotherapy that attacks all rapidly dividing cells in the body, GEFISTERIS 250 specifically targets cancer cells bearing EGFR mutations. This selective action means that healthy cells are largely spared, resulting in a more favorable side effect profile and better preservation of normal bodily functions during treatment.\n2. Superior Efficacy in EGFR-Mutant NSCLC\nClinical trials have consistently demonstrated that GEFISTERIS 250 and other EGFR-TKIs provide superior progression-free survival compared to chemotherapy in patients with EGFR-mutant NSCLC. Response rates typically range from 60-80% in appropriate patient populations, with many patients experiencing significant tumor shrinkage and symptomatic improvement within weeks of starting treatment.\n3. Improved Quality of Life\nPatients taking GEFISTERIS 250 often report better quality of life compared to those receiving traditional chemotherapy. The medication's targeted nature results in fewer debilitating side effects such as severe nausea, hair loss, and profound fatigue. Many patients can continue working, traveling, and engaging in normal daily activities while on treatment.\n4. Convenient Oral Administration\nGEFISTERIS 250's once-daily oral dosing eliminates the need for frequent hospital visits for intravenous chemotherapy infusions. Patients take one tablet daily at home, providing tremendous convenience and reducing the burden of treatment. This ease of administration contributes significantly to treatment adherence and patient satisfaction.\n5. Rapid Symptom Relief\nMany patients experience rapid improvement in cancer-related symptoms such as cough, shortness of breath, chest pain, and fatigue within the first few weeks of GEFISTERIS 250 treatment. This quick symptomatic relief can dramatically improve quality of life even before significant tumor shrinkage is visible on imaging studies.\n6. Extended Survival Benefits\nLong-term data demonstrates that appropriate use of EGFR-TKIs like GEFISTERIS 250 contributes to extended overall survival in patients with EGFR-mutant lung cancer. When used as part of a comprehensive treatment strategy, including potential sequential therapies after progression, patients can achieve survival times that were unimaginable before the advent of targeted therapies.\n7. Manageable Side Effect Profile\nWhile GEFISTERIS 250 does cause side effects, they are generally more manageable than those associated with traditional chemotherapy. Most side effects can be effectively controlled with supportive medications, dose modifications, or temporary treatment interruptions, allowing patients to continue benefiting from therapy.\n8. Quality Manufacturing by Steris Healthcare\nGEFISTERIS 250 benefits from Steris Healthcare's commitment to pharmaceutical excellence. Each tablet undergoes rigorous quality testing to ensure consistent potency, purity, and bioavailability. This quality assurance means patients receive reliable, effective medication with every dose.\nSide Effects of GEFISTERIS 250 (Gefitinib 250mg)\nWhile GEFISTERIS 250 offers significant therapeutic benefits, patients should be aware of potential side effects. Understanding these effects enables early recognition and appropriate management.\nCommon Side Effects (Affecting 20% or More of Patients):\nSkin Reactions: The most characteristic side effect of GEFISTERIS 250 is an acne-like rash, typically appearing on the face, chest, and back within the first few weeks of treatment. This rash, while cosmetically concerning for some patients, actually correlates with better treatment response. The rash can be managed with topical antibiotics, moisturizers, and sun protection. In severe cases, temporary dose reduction may be necessary.\nDiarrhea: Approximately 50-60% of patients experience diarrhea of varying severity. Mild diarrhea can often be managed with dietary modifications and over-the-counter anti-diarrheal medications like loperamide. Patients should stay well-hydrated and contact their healthcare provider if diarrhea becomes severe or persistent, as dose adjustments may be needed.\nNail Changes: Some patients develop paronychia (nail bed inflammation) or other nail abnormalities. Proper nail care, avoiding trauma to the nail beds, and wearing protective gloves during housework can help minimize these effects.\nDry Skin: Many patients experience skin dryness and itching. Regular use of fragrance-free moisturizers, gentle cleansers, and avoidance of hot showers can help manage these symptoms.\nMouth Sores: Oral mucositis or stomatitis can develop in some patients. Good oral hygiene, avoiding spicy or acidic foods, and using alcohol-free mouthwashes can provide relief.\nLess Common but Serious Side Effects:\nInterstitial Lung Disease (ILD): While rare (1-2% of patients), ILD is the most serious potential side effect of GEFISTERIS 250. Symptoms include sudden onset or worsening of respiratory symptoms such as difficulty breathing, cough, or fever. This requires immediate medical attention and usually necessitates permanent discontinuation of the medication.\nLiver Function Abnormalities: Elevated liver enzymes can occur, requiring regular monitoring through blood tests. Most cases are asymptomatic and reversible with dose modification or temporary discontinuation.\nEye Problems: Dry eyes, corneal erosion, or other ocular issues may develop. Regular use of lubricating eye drops and ophthalmological evaluation when symptoms occur can prevent serious complications.\nGastrointestinal Perforation: Though rare, serious gastrointestinal complications including perforation can occur, particularly in patients with underlying GI conditions.\nManagement Strategies:\nMost side effects can be effectively managed through:\n\nProactive supportive care and prophylactic measures\nDose modifications (reduction to 250mg every other day in some cases)\nTemporary treatment interruptions allowing recovery\nSymptomatic treatment with appropriate medications\nPatient education about early recognition and reporting of symptoms\n\nPatients should maintain open communication with their healthcare team, reporting any new or worsening symptoms promptly. Regular monitoring through clinical visits and laboratory testing helps identify and address side effects before they become serious.\nDosage and Administration Guidelines\nThe standard dose of GEFISTERIS 250 is one 250mg tablet taken orally once daily, with or without food. The tablet should be swallowed whole with water and should not be crushed or chewed. If a dose is missed and it's been less than 12 hours since the scheduled time, patients should take the missed dose. If more than 12 hours have passed, skip the missed dose and resume the regular schedule—never double up on doses.\nTreatment continues until disease progression or unacceptable toxicity occurs. Some patients remain on GEFISTERIS 250 for months or even years if they continue to benefit without prohibitive side effects. Dose modifications may be necessary based on individual tolerance, typically reducing the frequency to every other day rather than lowering the individual dose.\nPrecautions and Important Considerations\nPatients taking GEFISTERIS 250 should be aware of several important precautions. The medication can cause harm to developing fetuses, so women of childbearing potential must use effective contraception during treatment and for at least two weeks after the last dose. Breastfeeding should be avoided during treatment and for two weeks after completion.\nGEFISTERIS 250 can interact with medications that affect stomach acid, including proton pump inhibitors and H2-receptor antagonists. If antacids are needed, they should be taken several hours apart from GEFISTERIS 250. The medication may also interact with certain other drugs metabolized by the liver, so patients should inform their healthcare provider about all medications, supplements, and herbal products they're taking.\nRegular monitoring is essential during GEFISTERIS 250 treatment, including periodic liver function tests, pulmonary symptom assessment, and clinical evaluation for skin and other toxicities. Patients should avoid prolonged sun exposure and use high-SPF sunscreen, as the medication can increase photosensitivity.\nConclusion\nGEFISTERIS 250 represents a transformative treatment option for patients with EGFR-mutant non-small cell lung cancer, offering targeted, effective therapy with a manageable side effect profile. Manufactured by Steris Healthcare with unwavering commitment to quality and patient outcomes, GEFISTERIS 250 delivers Gefitinib 250mg in a formulation designed for optimal bioavailability and consistent therapeutic effect.\nThe medication's precision targeting of cancer-driving mutations, combined with convenient oral administration and generally tolerable side effects, makes GEFISTERIS 250 an excellent choice for eligible patients. While side effects do occur and require monitoring and management, the potential benefits—including tumor response, symptom improvement, extended progression-free survival, and enhanced quality of life—often significantly outweigh the risks for appropriately selected patients.\nSuccess with GEFISTERIS 250 requires partnership between patients and their healthcare teams. Molecular testing to confirm EGFR mutation status before treatment, adherence to the prescribed regimen, proactive management of side effects, and regular monitoring all contribute to optimal outcomes. For many patients with EGFR-mutant lung cancer, GEFISTERIS 250 offers not just treatment, but genuine hope for extended, quality life.\nAs personalized medicine continues to evolve, medications like GEFISTERIS 250 exemplify the power of matching treatments to individual tumor characteristics. Steris Healthcare's commitment to delivering this advanced therapy with assured quality and accessibility ensures that more patients can benefit from the remarkable advances in targeted cancer treatment that Gefitinib 250mg represents.\n", "price": 2760.0, "discountamount": 828.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "food", "Call", "Uses", "Rash", "Note", "NSCLC", "Email", "nausea", "Dosage", "spread", "WhatsApp", "diarrhea", "Gefitinib", "treatment", "One tablet", "GEFISTERIS", "information", "sterispharma", "consultation", "sterisonline", "Side Effects", "cancer cells", "targeted therapy", "Regular monitoring", "healthcare provider", "small cell lung cancer", "healthcare professional", "specific EGFR mutations", "epidermal growth factor receptor", "potential liver function alterations" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1530, "imageuri": "https://productimages.withfloats.com/actual/667d25ffb56721898510e93e.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d25ffb56721898510e93e.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T10:56:06.808Z", "updatedon": "2025-12-24T09:35:26.473Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gefitinib-250mg/1530", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GEFISTERIS 250", "category": "Oncology", "tags": [ "gefitinib 250 mg uses", "", "gefitinib 250 mg online purchase", "", "gefitinib 250 mg tablets price in india", "non-small cell lung cancer (NSCLC).", "triggered by chemotherapy.", "cancer biology.", "Superior Efficacy in EGFR-Mutant NSCLC" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6662e3b87247ae19c482b97c", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Enzalutamide 40mg", "description": "Enzalutamide 40 mg capsules represent a breakthrough in targeted therapy for advanced prostate cancer, particularly in metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). This second-generation androgen receptor inhibitor works by disrupting multiple steps in the androgen signaling pathway, offering patients a chance to slow disease progression, reduce tumor burden, and extend survival even after other treatments fail. Administered as a once-daily oral capsule, enzalutamide 40 mg provides four capsules per day (total 160 mg), making it convenient for long-term use in clinical settings where hormone therapy alone proves insufficient.​\n\nPatients often turn to enzalutamide when facing rising PSA levels despite androgen deprivation therapy (ADT), experiencing bone pain, or dealing with cancer spread to lymph nodes or distant sites. Its high affinity for androgen receptors—5-8 times stronger than first-generation antiandrogens like bicalutamide—ensures potent blockade without agonist activity, translating to real-world benefits like delayed chemotherapy needs and improved quality of life during treatment.​\n\nProduct Use and Indications\nEnzalutamide 40 mg primarily treats metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with docetaxel or progressing despite ADT. The FDA and EMA approvals extend to non-metastatic CRPC (nmCRPC) with high-risk biochemical recurrence and metastatic castration-sensitive prostate cancer (mCSPC) alongside ADT, based on landmark trials like AFFIRM, PREVAIL, PROSPER, and ARCHES.​\n\nKey uses include:\n\nSlowing tumor growth in hormone-refractory stages by inhibiting androgen-driven proliferation.\n\nReducing skeletal-related events like fractures or spinal cord compression in bone metastases.\n\nDelaying progression to chemotherapy in pre-chemotherapy mCRPC, with PREVAIL showing 17-month median radiographic progression-free survival (rPFS) versus 4 months for placebo.​\n\nIn mCSPC, ARCHES trial data demonstrated 61% risk reduction in progression or death when combined with ADT. Clinicians monitor PSA response (≥50% decline in 70-80% of patients) and imaging every 3 months to assess efficacy.​\n\nMechanism of Action\nEnzalutamide 40 mg exerts a threefold blockade on androgen receptor (AR) signaling: it competitively inhibits androgen binding to AR (with affinity rivaling dihydrotestosterone), prevents nuclear translocation of the ligand-receptor complex, and disrupts DNA binding and coactivator recruitment at androgen response elements. This comprehensive inhibition downregulates oncogenes like TMPRSS2-ERG fusion genes common in prostate cancer, inducing apoptosis and halting cell proliferation without lowering systemic testosterone levels.​\n\nUnlike earlier antiandrogens, enzalutamide avoids partial agonist effects, ensuring pure antagonism even in AR-overexpressing tumors. Its active metabolite, N-desmethyl enzalutamide (via CYP2C8), contributes 30% to activity, with steady-state levels achieved in 4 weeks.​\n\nKey Benefits\nExtended Progression-Free Survival: In PREVAIL (pre-chemo mCRPC), median overall survival reached 32.4 months versus 30.2 for placebo; PROSPER (nmCRPC) delayed metastasis by 22 months.​\n\nPSA Response and Tumor Shrinkage: 78% PSA90 response rate; radiographic responses in 29% with measurable disease.​\n\nQuality of Life Preservation: Delays pain progression (hazard ratio 0.40) and chemotherapy (by 17 months), maintaining daily function.​\n\nBone Protection: Reduces fractures by 30% in high-risk patients via AR inhibition in osteoblasts.​\n\nCombination Synergy: Enhances ADT efficacy in mCSPC, cutting death risk by 33% per ARCHES.​\n\nThese benefits position enzalutamide 40 mg as a cornerstone in modern prostate cancer protocols, especially for fit patients tolerating oral therapy.​\n\nSide Effects\nEnzalutamide 40 mg carries a manageable profile, with most effects dose-related and reversible upon discontinuation.\n\nCommon Side Effects\nFatigue/Asthenia (34-50%): Often mild, peaking in first months; rest and nutrition help.\n\nArthralgia/Myalgia (14-21%): Joint/muscle pain managed with NSAIDs.\n\nHot Flashes (20%): Androgen blockade mimic; hydration aids.\n\nHeadache/Dizziness (12-19%): Transient; avoid driving if severe.\n\nHypertension (6-13%): Monitor BP monthly; antihypertensives as needed.\n\nGI Issues (diarrhea 12%, nausea 11%): Antiemetics support compliance.​\n\nSerious Side Effects\nSeizures (0.9%): Highest risk in epileptics or brain mets; EEG baseline, avoid triggers.\n\nPosterior Reversible Encephalopathy (PRES): Rare (<0.1%); headache, confusion—MRI confirms.\n\nFalls/Fractures (15% increased risk): Due to weakness/falls; DEXA scans recommended.\n\nCardiac Events (2-5%): MI/arrhythmias; ECG monitoring in CVD history.\n\nHepatic Injury (1%): ALT/AST elevation; monthly labs first 3 months.​\n\nDiscontinuation occurs in 8-10%; supportive care mitigates most.​\n\nDosage and Administration\nStandard dose: 160 mg (four 40 mg capsules) once daily, with or without food. Swallow intact; no crushing. Adjust for CYP2A4 inducers (e.g., rifampin—increase to 240 mg) or strong inhibitors (reduce to 80 mg). Continue until progression/toxicity; no dose interruptions beyond 28 days without reassessment.​\n\nPrecautions and Monitoring\nContraindicated in pregnancy (teratogenic; absolute contraception for men/ partners). Screen for seizure history; CYP2C8/3A4 interactions (e.g., ketoconazole). Baseline LFTs, PSA, testosterone; imaging q8-12 weeks. Elderly (>75) monitor falls.​\nConclusion\nEnzalutamide 40 mg stands as a transformative therapy, empowering prostate cancer patients with prolonged control over aggressive disease through precise AR inhibition. Balancing robust efficacy—evidenced by landmark trials delaying metastasis and death—with proactive side effect management, it enhances survival and daily living. Patients achieve meaningful milestones, from family events to travel, underscoring its role in personalized oncology. Consult oncologists for integration into care plans, ensuring optimal outcomes in this challenging journey.\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\n\n\n\n\n\n\n\n\n", "price": 10781.0, "discountamount": 3235.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Call", "Email", "doctor", "product", "fatigue", "WhatsApp", "treatment", "schedules", "ENZULAMIDE", "monitoring", "hot flashes", "information", "sterisonline", "hypertension", "sterispharma", "prostate cancer", "Enzalutamide 40mg", "prescribed dosages", "androgen receptors", "cancer cell growth", "Common side effects", "comprehensive guidance" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1527, "imageuri": "https://productimages.withfloats.com/actual/667d2a356c582d228f45a098.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d2a356c582d228f45a098.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T10:40:56.587Z", "updatedon": "2026-01-21T08:51:15.552Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/enzalutamide-40mg/1527", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ENZULAMIDE 40", "category": "Oncology", "tags": [ "enzalutamide 40 mg side effects", "enzalutamide 40 mg brands in india", "enzalutamide 40 mg uses in hindi", "enzalutamide 40 mg dosage", "advanced prostate cancer", "prostate cancer", "metastatic castration-resistant prostate cancer", "enzalutamide 40mg tablets", "enzalutamide 40 mg capsule", "enzalutamide 40mg uses", "enzalutamide 40mg dosage", "enzalutamide 40mg price in india", "enzalutamide 40mg composition", "enzalutamide 40mg working mechanism", "enzalutamide 40mg side effects", "enzalutamide 40mg benefits", "enzalutamide 40mg drug information", "enzalutamide 40mg therapy details", "enzalutamide 40mg oral capsule", "enzalutamide 40mg treatment option", "enzalutamide 40mg pharmaceutical uses", "enzalutamide 40mg branded tablets", "enzalutamide 40mg generic medicine", "enzalutamide 40mg manufacturer in india", "what is enzalutamide 40mg used for", "how enzalutamide 40mg works", "is enzalutamide 40mg safe", "enzalutamide 40mg tablet information", "enzalutamide 40mg dosage guidelines" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }